{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:36:31Z","timestamp":1777512991093,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81501910"],"award-info":[{"award-number":["81501910"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Guangdong Provinve","award":["2018A030307025"],"award-info":[{"award-number":["2018A030307025"]}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2015GXNSFCA414001"],"award-info":[{"award-number":["2015GXNSFCA414001"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","award":["2015GXNSFDA139019"],"award-info":[{"award-number":["2015GXNSFDA139019"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangxi science and technology project","award":["Guikehe1599005-2-12"],"award-info":[{"award-number":["Guikehe1599005-2-12"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.canlet.2018.11.038","type":"journal-article","created":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T01:13:50Z","timestamp":1544318030000},"page":"135-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis"],"prefix":"10.1016","volume":"443","author":[{"given":"Guixin","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Lian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xixi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dantao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangming","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinjia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-6466","authenticated-orcid":false,"given":"Guanfeng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2018.11.038_bib1","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S1470-2045(13)70567-9","article-title":"Breast cancer in China","volume":"15","author":"Fan","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2018.11.038_bib2","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jbmr.2215","article-title":"TWIST1 expression in breast cancer cells facilitates bone metastasis formation","volume":"29","author":"Croset","year":"2014","journal-title":"J. Bone Miner. Res.: Off. J. Am. Soc. Bone and Min. Res."},{"key":"10.1016\/j.canlet.2018.11.038_bib3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2741\/3725","article-title":"Bone morphogenetic protein and bone metastasis, implication and therapeutic potential","volume":"16","author":"Ye","year":"2011","journal-title":"Front. Biosci."},{"key":"10.1016\/j.canlet.2018.11.038_bib4","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","article-title":"The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer","volume":"18","author":"Shimizu","year":"2012","journal-title":"Clin. Canc. Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2018.11.038_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.gde.2009.11.002","article-title":"Targeting the PI3K signaling pathway in cancer","volume":"20","author":"Wong","year":"2010","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.canlet.2018.11.038_bib6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1634\/theoncologist.2010-0402","article-title":"Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer","volume":"16","author":"Hernandez-Aya","year":"2011","journal-title":"Oncology"},{"key":"10.1016\/j.canlet.2018.11.038_bib7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1186\/1471-2407-10-425","article-title":"LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells","volume":"10","author":"Shin","year":"2010","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2018.11.038_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1158\/1535-7163.MCT-11-0474","article-title":"Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor","volume":"11","author":"Maira","year":"2012","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2018.11.038_bib9","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-12-0714","article-title":"A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors","volume":"18","author":"Hong","year":"2012","journal-title":"Clin. Canc. Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.canlet.2018.11.038_bib10","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1535-7163.MCT-09-0954","article-title":"Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor","volume":"9","author":"Mallon","year":"2010","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2018.11.038_bib11","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1021\/jm9014982","article-title":"Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase\/mammalian target of rapamycin inhibitors: discovery of PKI-402","volume":"53","author":"Dehnhardt","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2018.11.038_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10585-005-0365-9","article-title":"An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis","volume":"22","author":"Luu","year":"2005","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.canlet.2018.11.038_bib13","first-page":"204","article-title":"Osteoclastogenesis--current knowledge and future perspectives","volume":"8","author":"Yavropoulou","year":"2008","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.canlet.2018.11.038_bib14","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2018.11.038_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2018.11.038_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cytogfr.2014.01.002","article-title":"RANKL\/RANK - from bone physiology to breast cancer","volume":"25","author":"Sigl","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.canlet.2018.11.038_bib17","series-title":"Breast Cancer Metastasis to the Bone\u202f: Mechanisms of Bone Loss","author":"Chen","year":"2010"},{"key":"10.1016\/j.canlet.2018.11.038_bib18","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.11.038_bib19","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1158\/0008-5472.CAN-04-4188","article-title":"Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo","volume":"65","author":"van der Pluijm","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2018.11.038_bib20","doi-asserted-by":"crossref","first-page":"8742","DOI":"10.1158\/0008-5472.CAN-06-2490","article-title":"Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer","volume":"67","author":"Buijs","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2018.11.038_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ccell.2014.11.025","article-title":"14-3-3zeta turns TGF-beta\u2019s function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2","volume":"27","author":"Xu","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2018.11.038_bib22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2018.11.038_bib23","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1002\/cncr.26165","article-title":"Phase 1\/2 study of everolimus in advanced hepatocellular carcinoma","volume":"117","author":"Zhu","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2018.11.038_bib24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2018.11.038_bib25","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/bjc.2014.628","article-title":"MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity","volume":"112","author":"Cebulla","year":"2015","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2018.11.038_bib26","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms13021886","article-title":"The mTOR signalling pathway in human cancer","volume":"13","author":"Populo","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2018.11.038_bib27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/138920207782446160","article-title":"The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications","volume":"8","author":"Arcaro","year":"2007","journal-title":"Curr. Genom."},{"key":"10.1016\/j.canlet.2018.11.038_bib28","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1002\/jbmr.114","article-title":"NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells","volume":"25","author":"Martin","year":"2010","journal-title":"J. Bone Miner. Res.: Off. J. Am. Soc. Bone and Mineral Res."},{"key":"10.1016\/j.canlet.2018.11.038_bib29","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/ijc.29040","article-title":"BYL719, a new alpha-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma","volume":"136","author":"Gobin","year":"2015","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2018.11.038_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1756-8722-6-88","article-title":"Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics","volume":"6","author":"Akinleye","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2018.11.038_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14737140.2015.961429","article-title":"PI3K\/AKT\/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies?","volume":"15","author":"Abraham","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.canlet.2018.11.038_bib32","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canlet.2018.11.038_bib33","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/annonc\/mdu021","article-title":"Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann. Oncol.: Off. J. Europ. Soc. Med. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518307043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518307043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,26]],"date-time":"2018-12-26T10:19:18Z","timestamp":1545819558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383518307043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":33,"alternative-id":["S0304383518307043"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2018.11.038","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2018.11.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}